Robert Silva

Rob joined MindMed as Vice President, Head of Development in May 2022. Prior to joining MindMed, Rob held senior leadership positions at Zogenix Inc., Sunovion Pharmaceuticals and Ipsen Bioscience, leading global drug development teams focused on psychiatry and neurology indications and working to advance new treatments for difficult to treat disorders. Rob received his PhD from City University of New York and completed a post-doctoral fellowship at Columbia University College of Physicians and Surgeons working in the area of apoptotic cell death in movement disorders.